Rapid detection of genetic mutations related to a patient's drug metabolism status

AutoGenomics and Gentris Form Strategic Alliance to Launch Clinical Pharmacogenomic Diagnostics to incorporate key pharmacogenomic markers onto an automated molecular diagnostics platform

28-Jul-2004

AutoGenomics, Inc. and Gentris Corporation have announced a collaboration today that will accelerate market introduction of a series of panels in pharmacogenomic testing. This alliance will focus on the integration of Gentris' current pipeline of CYP450 diagnostic products onto the AutoGenomics' fully-integrated and automated INFINITI(TM) Platform. This combination will enable rapid detection of genetic mutations related to a patient's drug metabolism status, allowing physicians to administer therapies with the best chance of a beneficial outcome while reducing the likelihood of serious adverse events.

"Gentris has an established track record in developing pharmacogenomic tests with an clear understanding of the regulatory requirements," noted Fareed Kureshy, President & CEO of AutoGenomics. "This alliance will leverage these strengths and bring pharmacogenomic testing to near patient testing, realizing the true benefits of personalized medicine."

"AutoGenomics has developed a multiplexing platform that has simplified genomic testing through automation," said Michael Murphy, Gentris President & CEO. "Clearly the shared vision of Gentris and AutoGenomics will help to decrease serious adverse drug reactions, which are the fourth leading cause of death and the fifth leading cause of illness in the United States," according to Murphy.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures